The involvement of anti-PD-L1 mAbs in the increase of sPD-L1, regardless of tumor histotypes or treatment schedules, was enforced by the comprehensive analysis performed on all patients treated with anti-PD-L1 mAbs, alone or in combination. This evidence concerns the gene SPDL1 and neoplasm.